and Legal Implications of Programs to Redress Injuries Caused by Biomedical and Behavioral Research. Volume 1. Washington, D.C.: Government Printing Office.

Walters, L.B. 1993a. Letter from Dr. LeRoy B. Walters, Chair, Recombinant DNA Advisory Committee, to Dr. Bernadine Healy, Director, National Institutes of Health. January 6, 1993.

Walters, L.B. 1993b. Letter from Dr. LeRoy B. Walters, Chair, Recombinant DNA Advisory Committee, to Dr. Bernadine Healy, Director, National Institutes of Health. June 28, 1993.

42 USCA §300aa-1 to -33 (1989)

45 C.F.R. 46.116(a)(b)

Va. Code Sections 38.2-5000 et seq. [1990 Real. Vol.]

Front Matter (R1-R14)

Executive Summary (1-26)

1 Introduction (27-35)

2 Women's Participation in Clinical Studies (36-74)

3 Justice in Clinical Studies: Guiding Principles (75-83)

4 Scientific Considerations (84-107)

5 Social and Ethical Considerations (108-127)

6 Legal Considerations (128-174)

7 Risks to Reproduction and offspring (175-202)

8 Implementation (203-212)

Appendix A: Reports on Women's Participation in Clincal Studies, 1977-1993 (213-232)

Appendix B: NIH Revitalization Act of 1993, Public Law 103-43 (June 10, 1993), Excerpt (233-236)

Appendix C: DES Case Study (237-242)

Appendix D: Compensation Systems for Research Injuries (243-252)

Appendix E: Committee Biographies (253-260)

Index (261-271)